Eagle Pharmaceuticals, Inc. (“Eagle” or “the Company”) (Nasdaq:EGRX) today announced that the U. S. Food and Drug Administration (FDA) has approved Ryanodex (dantrolene sodium) for injectable suspension indicated for the treatment of malignant hyperthermia (MH), along with the appropriate supportive measures. MH is an inherited and potentially fatal disorder triggered by certain anesthesia agents in genetically susceptible individuals. FDA had designated Ryanodex as an Orphan Drug in August 2013. Eagle has been informed by the FDA that it will learn over the next four to six weeks if it has been granted the seven year Orphan Drug market exclusivity.
Med-Chemist : "Quintessential Medicinal Chemistry"
Showing posts with label Ryanodex (dantrolene sodium). Show all posts
Showing posts with label Ryanodex (dantrolene sodium). Show all posts
Tuesday, July 29, 2014
Subscribe to:
Posts (Atom)